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Background: The current, arbitrarily defined gold standard for the diagnosis of
H. pylori infection requires histologic examination of two specially stained
antral biopsy specimens. However, routine histology is potentially limited in
general clinical practice by both sampling and observer error. The current study
was designed to examine the diagnostic performance ofinvasive and non-inva-
sive H. pylori detection methods that would likely be available in general clini-
cal practice.
Methods: The diagnostic performance of rotating clinical pathology faculty
using thiazine staining was compared with that of an expert gastrointestinal
pathologist in 38 patients. In situ hybridization stains of adjacent biopsy cuts
were also examined by the expert pathologist for further comparison. Receiver
operator characteristic (ROC) analysis was performed to evaluate whether the
diagnostic performance of the expert pathologist differed depending upon the
histologic method employed. A similar analysis was made to evaluate the diag-
nostic performance of pathology trainees relative to the expert. In the absence
of an established invasive gold standard, non-invasive testing methods (rapid
serum antibodies, formal Elisa antibodies and carbon-14 urea breath testing)
were evaluated in 74 patients by comparison with a gold standard defined using
a combination ofdiagnostic tests.
Results: Using either rapid urease testing of biopsy specimens or urea breath
testing as the gold standard for comparison, the diagnostic performance of the
rotating clinical pathology faculty was inferior to that of the expert gastroin-
testinal pathologist especially with regard to specificity (e.g., 69 percent for the
former versus 88 percent, with the latter relative to rapid urease testing).
Although interpretation of in situ hybridization staining by the expert appeared
to have an evenhigher specificity, ROC analysis failed to show a difference. The
mean ROC areas for thiazine and in situ hybridization staining for trainee
pathologists relative to the expert were 0.88 and 0.94, respectively. In untreated
patients, urea breath testing had a sensitivity and specificity of 100 percent as
compared with thiazine staining with a sensitivity of83 percent and a specifici-
ty of97 percent. Post-therapy, breath testing had a sensitivity of 100 percent but
a specificity ofonly 86 percent as compared with invasive testing with a sensi-
tivity and specificity of 100 percent. Rapid serum antibody testing and formal
Elisa antibody testing agreed in 93 percent ofcases (Kappa 0.78) with the rapid
test being correct in three of the four disagreements
Conclusions: The current study illustrates a number of realities regarding H.
pylori diagnosis. There is no diagnostic gold standard in general clinical prac-
tice. Accurate interpretation ofspecially stained slides is a learned activity with
atendency towards overdiagnosis early on. Ureabreath testing is likely tobe the
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diagnostic method of choice for untreated patients in general clinical practice
although antibody testing is almost as accurate. Rapid antibody tests are at least
as accurate as formal Elisa antibody tests. Urea breath testing is useful for con-
firming cure after therapy, but false-positive results may occur in some patients.
INTRODUCTION
The current arbitrarily defined gold standard for the diagnosis ofHelicobacterpylori
infection consists of histologic examination of two specially-stained antral biopsy speci-
mens [1, 2]. Studies with the Giemsa, Warthin Starry or Genta stains have revealed an
accuracy that may be as high as 98 percent in expert hands [2, 3]. However, histology may
be less accurate in general clinicalpractice for avariety ofreasons. Sampling erroris com-
monly cited as apotential cause ofinaccurate histological diagnosis so that certain author-
ities have recommended that additional specimens be taken from the lesser curve and/or
the gastric body to increase the diagnostic yield [4]. Additional biopsy specimens may be
especially important in patients taking antisecretory therapy. Histology is also potentially
limited in clinical practice by inter- and intra-observer variability depending on the exper-
tise ofthe examining pathologist [5, 6]. Moreover, none ofthe currently accepted special
stains used to identify H. pylori infection are specific for the organism so that diagnosis is
made upon morphologic characteristics alone [1, 2]. The most specific method for diag-
nosing H. pylori infection is culture ofbiopsy specimens, but this method is highly insen-
sitive because of the fastidiousness of the organism [1, 2]. Consequently, routine culture
cannot be considered an acceptable gold standard for general clinical practice. Other spe-
cific invasive methodologies such as polymerase chain reaction (PCR)b or immunohisto-
chemistry are also limited in clinical practice because ofthe expertise required to perform
these studies [7, 8].
A variety ofhighly accurate, non-invasive diagnostic tests forH. pyloriinfection have
recently become available [1, 2]. These include rapid office-based antibody tests, formal
Elisa antibody testing, and urea breath testing (both carbon 13 and carbon 14 tests) [1, 2,
6, 9-12]. In the absence of a true gold standard for diagnosis, these newer methodologies
have been compared against a battery ofother methods to demonstrate their accuracy [11,
12]. From a statistical point of view, this approach is limited by the inclusion of the test
method under consideration in the arbitrarily defined gold standard itself, so that it can be
argued that the method under consideration is actually being compared with itself. An
alternative approach is to compare the test methodology with a gold standard that is
defined by concordance of two or more other methodologies (for example, histology,
rapid urease testing or breath testing) [9]. An obvious limitation of this approach is that
patients with discordant gold standard component test results have to be excluded from
analysis. Little is known about the accuracy of these newer, non-invasive methodologies
in general clinical practice since they too may be limited by interpretation bias (for exam-
ple, where to define the transition from positive to negative in terms of the magnitude of
the test response).
The aims of the current study were to determine the accuracy of invasive and non-
invasive H. pylori detection methods in general clinical practice. We chose to examine
methods that would likely be available in most diagnostic centers and that would require
minimal expertise for accurate interpretation ofresults.
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METHODS
General
All patients presenting to the Gastroenterology Division of the University of
Pennsylvania for upper endoscopy were invited to participate in the current study. Patients
who were pregnant, breast feeding, had used antibiotics or bismuth preparations within
four weeks or proton pump inhibitors within one week, or had previously undergone gas-
tric surgery were excluded. Patients who had received specific anti-H. pylori therapy in
the past were included providing that this treatment had been completed at least four
weeks prior to testing. Three antral biopsy specimens (within 3 cm of the pylorus) were
taken in all patients at the time oftheirendoscopy. Two specimens were submitted forhis-
tological analysis, and one was used for rapid urease testing (CLO test, Delta West,
Bentley, Australia). To determine the intra-observer reproducibility of histology for the
diagnosis of H. pylori infection, the expert gastrointestinal pathologist read 16 randomly
selected antral biopsy slides on three separate days over a four-week period in a different
random order at each session. There was disagreement as to the presence or absence ofH.
pylori organisms in two of 16 cases. In each case, the slides were read as negative twice
but positive once with an organism burden of one on a scale of 0 to three on both occa-
sions. There was complete agreement amongst all three readings in the remaining 14
cases. The intra-class correlation coefficient was 0.82 with a P value for a difference
between replicates of 0.62 [6]. All studies had the approval of the committee on studies
involving humans and the radiation safety committee of the University of Pennsylvania
and were only performed after the patients provided informed consent.
Invasive testing
In order to assess the diagnostic performance ofstandard histological methods for H.
pylori diagnosis in general clinical practice, we compared the sensitivity and specificity
ofthiazine staining forH. pylori diagnosis (relative to rapid urease testing and ureabreath
testing) as assessed by rotating clinical pathology faculty with the results obtained by the
expert gastrointestinal pathologist in 38 Bouin's-fixed paraffin-imbedded antral biopsies.
To further evaluate the diagnostic performance of the expert gastrointestinal pathologist
using standard histology, the latter's sensitivity and specificity with thiazine staining were
compared with in situ hybridization staining of adjacent cuts of all 38 biopsy specimens
[13]. In situ hybridization was performed using a 22 base biotin-labeled oligonucleotide
probe complementary to a portion ofthe H. pylori 16 s ribosomal RNA at a final concen-
tration of 1 pg/ml using manual capillary action technology on the Microprobe Staining
System (Fisher Scientific, Boston, Massachussetts) with modifications as previously
described. Receiver operator characteristic (ROC) analysis ofthiazine staining and in situ
hybridization for H. pylori detection relative to rapid urease and urea breath testing was
determined for the experienced gastrointestinal pathologist for a more detailed compari-
son ofstandard histological methods with our in situ hybridization technique forH. pylori
detection [14]. ROC analysis is independent of disease prevalence making it possible to
determine sensitivity and specificity over all "cut-off' points. In the absence of a "true"
gold standard for H. pylori diagnosis, we chose to keep the rapid urease and urea breath
tests as invariant tests for these comparisons since it is generally easy to distinguish pos-
itive from negative tests with these methods. This in no way implies that either the rapid
urease or urea breath test is the "true" gold standard for diagnosis. Instead, one test must
be kept constant such that relative comparisons can be made. ROC analysis was also per-
formed on five resident pathologists in training relative to the expert gastrointestinal
pathologist in order to determine how much experience was required for accurate H.
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pylori detection. For each ROC analysis, the observers graded on a scale of 1 through 5
their surety of the presence of H. pylori organisms (one being definitely not present, five
being definitely present). The area under the ROC curve was calculated for each analysis.
This value is a measure ofdiagnostic performance with a value of0.5 representing chance
and 1.0 representing perfect test performance [14]. The grading of thiazine and in situ
stains were done on separate occasions.
Non-invasive testing
The diagnostic performance ofnon-invasive testing methodologies was assessed first
by defining the gold standard using acombination ofresults from all tests in 74 study sub-
jects in a manner similar to those described by Cutler [11] and the Division ofAnti-infec-
tive Drug Products Center for Drug Evaluation and Research of the US Food and Drug
Administration (Dr. A. Hopkins, personal communication). These tests included evalua-
tion of two antral biopsy specimens stained with thiazine for the presence of organisms,
two antral biopsies stained with hematoxyllin and eosin for the presence of chronic
inflammation on routine histology [12] and one antral biopsy specimen, which was used
forrapid urease testing. Histological interpretation was performedby the same expert gas-
trointestinal pathologist who performed the invasive testing studies (see above). In addi-
tion, all patients underwent urea breath testing after ingestion of a capsule containing 1
pCi (37 IEq) carbon 14 urea (Trimed specialties, Charlottesville, Virginia) with subse-
quent collection of breath samples at five-minute intervals for 30 minutes [6].
Radioactivity of exhaled breath was measured in a scintillation counter in auto-DPM
mode with a calculated efficiency of greater than 98 percent and expressed as disintegra-
tions perminute (DPM). Apositive test with breath testing was defined as anincrease over
baseline of more than 100 DPMs. Antibody testing was performed on all patients using
two methodologies, the Flexure HP rapid serum test (SmithKline Diagnostics, San Jose,
California), which was performed in the office, and the HM CAP Elisa antibody test
(Enteric Products, Inc., Stony Brook, NewYork), which was performed on serum that was
mailed to a reference laboratory. For the former test, supernatant was removed after cen-
trifugation at 3200 RPM for 20 minutes and placed on Flexure HP cards [15]. A positive
test result was defined as the appearance of a pink colored test line in addition to a visible
control line. The latter test was performed after additional serum samples were coded and
transferred to SmithKline Diagnostics forquantitative Elisa assay using the HM CAP anti-
gen [16]. Elisa values greater than 2.2 were considered positive for H. pylori infection.
Using a combination of these testing methods, a pre-therapy true-positive diagnosis
was defined as the presence of four or more positive tests while a true-negative required
one or none positive. Patients with either two or three positive tests were considered non-
evaluable and were excluded from analysis. For post-therapy diagnosis, the second anti-
body test was removed from the above scheme, and a positive diagnosis post-therapy
required three or more of the four remaining tests to be positive. A negative diagnosis
required one or none of the four tests to be positive, and patients with two positive tests
were excluded from analysis. Statistical analysis were performed using Statistica 4.0
(Statsoft Inc., Tulsa, Oklahoma). Estimates of sensitivity and specificity were computed
in the usual manner, and comparisons between the two serological tests were performed
using percentage agreement and the chance adjusted agreement statistic, Kappa.
RESULTS
Rapid urease testing and urea breath testing detected H. pylori infection in 15/38 (39
percent) and 19/38 patients (50 percent), respectively. Using the rapid urease test as the
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Table 1. Sensitivity and specificity ofhistology forH.pylori diagnosis (n = 38).
Relative to rapid urease test Relative to urea breath test
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
Routine pathology 87 69 75 68
(Thiazine stain)
GI pathologist 87 88 75 91
(Thiazine stain)
GI pathologist 80 100 60 100
(In situ hybridization)
gold standard, thiazine staining ofantral biopsy specimens had a sensitivity of87 percent
and a specificity of69 percent forH. pylori detection when evaluated by the rotating clin-
ical pathology faculty (Table 1). When the same slides were examined by the expert gas-
trointestinal pathologist, the sensitivity of thiazine was unchanged but the specificity
increased to 88 percent. The sensitivity and specificity ofin situ hybridization in the expert
pathologist's hands was 80 percent and 100 percent, respectively, as compared with the
rapid urease test results (Table 1). Using urea breath testing as the gold standard, a simi-
lar trend occurred, although the sensitivity of histology was somewhat lower for all cal-
culations because urea breath testing identified more patients with H. pylori gastritis than
any other modality.
In order to determine whether the relative diagnostic performance ofthiazine and in
situ hybridization staining for H. pylori diagnosis was truly different in expert gastroin-
testinal pathologists' hands, ROC analysis was performed. ROC values did not differ sig-
nificantly between the two histological methods indicating equivalent test performance
(Table 2).
The relative diagnostic performance ofthiazine staining and in situ hybridization for
five pathologists in training, with the expert gastrointestinal pathologist serving as the
gold standard, is shown in Table 3. The mean ROC areas for thiazine staining and in situ
hybridization were 0.88 and 0.94, respectively. In addition, when asked which ofthe two
diagnostic methods was easier to interpret, four of the five trainees felt the in situ
hybridization stain to be superior, and the one trainee who felt that the thiazine stain was
superior actually performed better relative to the expert gastrointestinal pathologist with
the in situ stain (data not shown).
Table 2. Relative diagnostic performance ofthiazine and in situ hybridization staining for H.
pyloni diagnosis by the expert gastrointestinal pathologist (n = 38).
Relative to rapid urease test Relative to urea breath test
(ROCI values) (ROCI values)
Thiazine stain 0.86 0.74
In situ hybridization 0.87 0.79
1 ROC = receiver operator characteristic
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Table 3. Relative diagnostic performance oftwo histological methods forH.pylonidiagnosis by
five pathologists in training (n = 38).
Observer Thiazine stain relative to In situ hybridization relative to
expert GI pathologist expert GI pathologist
(ROC1 values) (ROCI values)
1 0.86 0.89
2 0.91 1.0
3 0.9 0.97
4 0.93 0.99
5 0.8 0.85
Average 0.88 0.94
l ROC = receiver operator characteristic.
Table 4. Sensitivity and specificity ofvarious testing methods H. pylori diagnosis (n = 74).1
Elisa Rapid serum
Pre-therapy Thiazine Rapid urease Chronic Urea breath antibody antibody
(n = 54) stain test gastritis test test test
Sensitivity (%) 83 91 91 100 91 91
Specificity (%) 97 100 100 100 94 100
Post-therapy
(n= 15)
Sensitivity (%) 100 100 100 100 N/A2 N/A2
Specificity (%) 100 100 93 86 N/A2 N/A2
I The gold standard for diagnosis is defined according to the scheme outlined in Methods.
2 N/A, not applicable.
Table 5. Analysis ofdiscordant antibody tests.
Rapid serum Rapid Urea
Patient antibody Elisal urease Thiazine breath Correct
number test value test stain test test
7006 Positive 1.6 Positive Positive Positive Rapid antibody
7026 Negative 2.5 Negative Negative Negative Rapid antibody
7029 Negative 2.5 Positive Positive Positive Elisa test
7051 Negative 2.5 Negative Negative Negative Rapid antibody
I A value greater than 2.2 is considered positive.
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Figure 1. Correlation between office-based rapid serum antibody testing and laboratory-
based formal Elisa antibody testing for H. pyloyi diagnosis in 58 patients not previously treat-
ed forH.pyloniinfection. Elisa testresults are shown along the x-axis (an Elisa value of> 2. 2 units
corresponds with a positive result). Rapid serum antibody test results are shown along the y-axis.
There was a 93 percent agreement between the twoH.pylori antibody test methods (Kappa = 0.78).
Of 74 patients evaluated with all non-invasive diagnostic tests, five were excluded
because they had indeterminate gold standard results. Fifty-four ofthe remaining patients
had not previously been treated forH.pylori infection, and 15 were post therapy. Twenty-
three ofthe 54 untreated patients were H. pylori positive by the gold standard, and one of
the 15 post-therapy patients was still infected. The sensitivity and specificity ofeach diag-
nostic test in the diagnosis ofH. pylori infection both pre- and post-therapy are shown in
Table 4. In untreated patients, invasive thiazine staining (the currently accepted gold stan-
dard fordiagnosis) had a sensitivity of83 percent and a specificity of97 percent. By com-
parison, the sensitivity and specificity of urea breath testing in this population was 100
percent. In evaluating H. pylori status post-therapy, the sensitivity and specificity ofinva-
sive testing with thiazine (for organisms) or hematoxyllin and eosin staining (for chronic
inflammation), or rapid urease testing (for urease detection) was 100 percent. Urea breath
testing had a sensitivity of 100 percent, but its specificity was only 86 percent.
Figure 1 illustrates the agreement between the two serologic tests in patients not pre-
viously treated for H. pylori infection, including four additional patients with indetermi-
nate gold standard results. Test results agreed in 54 of 58 patients (93 percent) with a
Kappa statistic of0.78. Test results disagreed in four patients (7 percent), three with neg-
ative rapid antibody results and positive Elisa tests and one with a positive rapid antibody
test and a negative Elisa test. The discordant antibody testresults are shown in more detail
in Table 5. In three of the four disagreements, the rapid antibody test was the correct test
when compared with other diagnostic modalities including rapid urease testing, thiazine
testing and urea breath testing.
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DISCUSSION
The current study makes clear a number of realities regarding H. pylori diagnosis.
First, there is no true diagnostic gold standard in general clinical practice. This is brought
out by the fact that the correlation between standard thiazine staining for H. pylori diag-
nosis and other non-invasive diagnostic methods (urea breath testing or rapid urease test-
ing) is closer when interpreted by an expert gastrointestinal pathologist as opposed to
rotating pathology faculty in a large teaching hospital. The major shortcoming appears to
be one of overdiagnosis since specificity is unacceptably low when slides are interpreted
by rotating pathology faculty. In keeping with our previous report [6], the initial speci-
ficity of in situ hybridization relative to thiazine staining suggested that the tendency for
over-diagnosis exists with expert pathologists as well. However, the current ROC analysis
suggested that this was not the case.
The ROC analyses of the pathologists in training suggest that the learning curve for
diagnosing H. pylori infection both by thiazine stain and by in situ hybridization is short.
ROC values for the trainees were all acceptable, but their diagnostic performance was
more favorable with the in situ method (area under the ROC curve of0.94) than with stan-
dard thiazine staining (0. 88). We interpret this data to suggest that a trained gastrointesti-
nal pathologist accurately diagnoses H. pylori infection using standard special stains most
of the time. In comparison, trainee pathologists are less accurate with standard stains, but
their accuracy approaches that of an expert if specialized methods such as in situ
hybridization are utilized. However, such methods are not routinely available and are,
thus, clearly beyond the scope ofroutine clinical practice. The results ofthe current study
do suggest that in situ hybridization may be useful for training pathologists in interpret-
ing H. pylori slides. Thus, the second reality ofthe current study regarding H. pylori diag-
nosis is that accurate interpretation of thiazine-stained slides is a learned activity.
The current study did not directly address the potential effect of sampling error on
invasive diagnostic results. Other investigators have suggested that this is a real consider-
ation affecting diagnostic yield [4]. In this regard, it is interesting to note that in the cur-
rent study, urea breath testing (which samples a much larger area of the gastric mucosa
than any of the biopsy-based tests) detected more potential infections than either rapid
urease testing or histology (thiazine staining and in situ hybridization). Thus, sampling
error may be a factor affecting test accuracy with diagnostic methods that depend upon
small pinch biopsies of the gastric mucosa.
Given the limitations of invasive testing in clinical practice, we chose to evaluate the
diagnostic performance of non-invasive diagnostic methods in previously untreated and
post therapy patients as possible clinical practice alternatives. The gold standard for com-
parison in these studies was devised using a combination oftests in order to limit the like-
lihood that the test underconsideration appeared less accurate than it actually was because
ofa gold standard inaccuracy. The limitations ofthis approach have been described above.
This methodology was chosen over a concordance method using invasive testing because
we feel that invasive testing has limitations even in the best hands. For diagnosis in
patients not previously treated forH. pylori infection, urea breath testing appears to be the
most accurate (i.e., the gold standard for clinical practice). While the current study
addresses only carbon 14 urea breath testing, it is likely that results with carbon 13 urea
breath testing would be similar. Previous studies on the diagnostic accuracy ofureabreath
testing have shown it to be an excellent test [6, 9, 11]. For post-therapy H. pylori diagno-
sis, the current data would suggest thatinvasive testing is most accurate. However, in eval-
uating patients post-therapy in general clinical practice, it is most important that the test
under consideration always correctly identify non-cured patients. Urea breath testing was
positive in all the non-cured patients in the current study. Its apparent shortcoming, in
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keeping with other investigators [11], was that it was occasionally positive in post-thera-
py patients who appeared to be cured by all other testing methods. This data could also be
interpreted to suggest thatureabreath testing is the most sensitive ofall methods fordeter-
mining failure to eradicate an infection. In order to determine which of these two possi-
bilities is true, patients with apparent false-positive urea breath tests will need to be re-
evaluated on a second occasion some time later to see whether the breath test becomes
negative (i.e., a false-positive initial breath test) or the other tests became positive (i.e., a
true-positive initial breath test). Further studies will be required to address this issue. Thus
the third reality ofthe current study regarding H. pylori diagnosis is that urea breath test-
ing is likely to be the diagnostic method of choice in general clinical practice for previ-
ously untreated patients. For post-therapy confirmation of H. pylori eradication, urea
breath testing is accurate, although there is a question regarding false-positive testing in
some patients.
In the absence ofurea breath testing, the next best diagnostic modalities in untreated
patients appear to be rapid antibody testing or rapid urease testing. Both these modalities
have specificities of 100 percent and sensitivities of91 percent, but the rapid antibody test
is likely to be more useful in routine clinical practice because it is non-invasive and less
costly. Rapid antibody testing is at least as accurate as formal Elisa testing [10, 17]. In the
current study, rapid antibody testing had similar sensitivity (91 percent) but a better speci-
ficity (100 percent versus 94 percent). In three of the four cases in which there was dis-
cordance between rapid antibody testing and formal Elisa testing, the rapid test was the
correct test. Thus, the fourth diagnostic reality of the current study is the fact that rapid
antibody testing is at least as accurate as formal Elisa testing and almost as accurate as
breath testing. There is no longer a need to send blood to a reference laboratory in order
to test for H. pylori antibodies, and antibody testing should remain the screening method
of choice for H. pylori diagnosis because of ease of performance and low cost. Whole
blood antibody testing is now being developed for routine office use, and it is likely that
whole blood antibody testing will ultimately replace serum antibody testing because of
ease ofuse, providing that it can be shown to be as accurate [18].
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